OK We use cookies to enhance your visit to our site and to bring you advertisements that might interest you. Read our Privacy and Cookies policies to find out more.

News Americas

Axim Biotechnologies plans to bring ORAXIMAX, a line of cannabigerol-based dental care products, on drugstore shelves by fall. (DTI/Photographs courtesy of Axim)
0 Comments Apr 13, 2015 | News Americas

New cannabigerol toothpaste to be introduced this year

Post a comment by Dental Tribune International

NEW YORK, USA: A new kind of oral care product could lead the way for cannabinoids in dentistry. Axim Biotechnologies, a New York-based firm that specializes in cannabinoid research and commercial hemp products, has unveiled a line of cannabigerol-based products that are expected to be on drugstore shelves by fall.

ORAXIMAX, the world's first oral care line containing cannabigerol (CBG), was introduced by Axim at a press conference in Manhattan earlier this year. CBG, the active ingredient in the company's dental range of toothpaste, dentifrice, oral rinse, oral gel and dental floss, is among a series of cannabinoid compounds found in the marijuana plant.

"It is known that certain cannabinoids act as effective anti-inflammatory, bactericidal, anti-proliferative, and regenerating agents. For these reasons, Axim has created a new category within the oral care consumer products market," Axim CEO Dr. George E. Anastassov told Dental Tribune Online.

According to Lekhram Changoer, Axim's chief technology officer, CBG is the precursor of the other well-known cannabinoids, such as cannabidiol and tetrahydrocannabinol, and responsible for most of cannabis' medical effects. "Industrial hemp contains numerous nonpsychoactive cannabinoids and essential amino acids," explained Changoer. "It also acts as a COX-2 inhibitor, similar to the well-known class of nonsteroidal anti-inflammatory drugs but without their side effects." Furthermore, Changoer stressed that the all-natural oral formulas should be able to provide sustainable prevention of decay, plaque, halitosis and gingival irritation.

According to the company, the new CBG-based products are not subject to FDA regulations because they are not considered medical. The patent-pending line is expected to be available online and in stores in the U.S. in about four months from now with a pricing similar to that of existing popular oral care brands available on the market.

In addition to their oral care solutions, the company plans to launch a range of CBG-based cosmetics, featuring baby powder, moisturizers, lotions, lip balm, shampoo, conditioner and body wash.

Hemp products from the nonpsychoactive part of the cannabis plant can legally be imported and sold in all 50 states, but growing the plant is illegal in the U.S. Therefore, Axim imports its products from overseas. In November 2014, the firm announced that its manufacturing facility headquarters will be in Almere, the Netherlands.

Post a comment Print  |  Send to a friend
Join the Discussion
All comments are subject to approval before appearing. Submit Comment